Skip to main content

Modern Era of Approved MS Disease Modifying Therapies

A timeline of the FDA approval of various disease modifying therapies for multiple sclerosis.

  • 1993 Interferon β-1b SQ (Betaseron®)
  • 1996 Interferon β-1a IM (Avonex® )
  • 1996 Glatiramer acetate SQ  (GA – Copaxone®)
  • 2000 Mitoxantrone IV (Novantrone®)
  • 2002 Interferon β-1a SQ (Rebif®)
  • 2004 Natalizumab IV (Tysabri®); OFF market Feb. 2005, back on market July 2006
  • 2010 Fingolimod PO (Gilenya®); Approved in 2018 for pediatric use.
  • 2012 Teriflunomide PO (Aubagio®)
  • 2013 Dimethyl fumarate PO (Tecfidera®)
  • 2015 Generic glatiramer acetate SQ (Glatopa, Sandoz)
  • 2016 X Daclizumab (Zinbryta) Removed from Market 2018
  • 2017 Ocrelizumab IV (Ocrevus®); Generic glatiramer acetate (Mylan product)
  • 2019 Siponimod PO (Mayzent®); Cladribine PO (Mavenclad®); Diroximel Fumarate PO (Vumerity®); Generic fingolimod x 3
  • 2020 Ozanimod PO (Zeposia®); Ofatumumab SQ (Kesimpta®); Monomethyl fumarate (Bafiertam®); Generic dimethyl fumarate (Mylan)

 

Close Menu
Translate Site »
Skip to content